Avant Immunotherapeutics said today it is changing its name to Celldex Therapeutics as part of the merger the two companies announced in the first quarter. The Needham, MA-based company (NASDAQ: [[ticker:AVAN]]) will change its ticker symbol to (NASDAQ: [[ticker:CLDX]]), starting Oct. 1. The company’s board also announced that Anthony Marucci, who has worked as interim CEO since May, has gotten the job on a permanent basis. Celldex is developing antibody drugs to deliver vaccines directly to their therapeutic targets.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
